Key Highlights
- Sales for the quarter ended October 2, 2026 reached USD 83.4 million, which is 12.0% under USD 94.7 million, mainly because a USD 25.9 million delayed China shipment was recognized in the prior year.
- Excluding that prior-year shipment, sales would have grown 21.1% from a USD 68.8 million base, with EMEA up 31% and the Americas up 14%, per the filing.
- Profit came in at USD 5.6 million, or USD 0.11 a diluted share, down from USD 8.9 million (USD 0.18), and gross Margin slid to 70.9% versus 82.2%.
- Available-for-sale cash and investments increased to USD 206.4 million, compared with USD 181.5 million on July 3, 2026, while September brought news of a USD 50.0 million buyback authorization.
A Distorted Comparison Behind the Decline
STAAR Surgical (NASDAQ:STAA) submitted its fiscal third quarter results on November 4, 2026. The company manufactures Implantable Collamer Lenses, which are soft lenses placed inside the eye, without removing the natural lens, to correct vision. The prior-year third quarter included USD 25.9 million recognized from the December China Shipment, a 2024 order that had been placed and delivered but whose Revenue was held back. Asia Pacific sales declined 20%, driven by China, while Japan dropped 8% due to currency and was essentially flat without it. Nine-month net sales surged 48.9% to USD 270.5 million, or 75.5% excluding the shipment. EMEA climbed 31%, or 51% without the Middle East, where sales slipped 2%, and Americas grew 14% on United States and Latin America gains. Currency trimmed net sales by USD 1.0 million.
Gross Margin Trails the 75% Target
The margin of 70.9% compares with 82.2%, and the earlier figure carried a 6.7 point lift from the prior-year shipment; removing that effect puts last year at 75.5%. Higher production costs, tied to thin second quarter output during an enterprise software rollout, along with freight increases, levies on US-made goods destined for China and reserves against inventory nearing expiry, were cited by management as the drivers. The company does not foresee reaching its 75% target gross margin in 2026, though it expects improvement in the fourth quarter. Selling, general and administrative expense was USD 53.7 million versus USD 59.4 million, selling and Marketing took 29.2% of sales compared with 24.8%, and Research and Development equaled 12.5% of sales.
Swiss Production, Software Fixes and a Cash Build
Since the third quarter of 2026, every new lens destined for China has come from Swiss facilities, which management thinks will trim duty expense. Implementing the enterprise software required a great deal of hands-on intervention, and the most serious glitches are expected to be cleared by year end 2026. Excluding the shipment, the prior-year quarter would have shown a net loss of USD 6.3 million, or USD 0.13 per share, so the comparison with a profitable prior year is distorted. Risks include dependence on Asian demand, reliance on distributors, tariffs and the Chinese economy. No shares were repurchased in the quarter, and the filing gave no price information or numeric outlook.
Where Things Stand
Last year's one-time USD 25.9 million China shipment explains the 12% drop, and excluding it sales rose 21.1%. STAAR Surgical (NASDAQ:STAA) still earned less than a year earlier, and management blames its thinner margin on transitory issues. Next markers are fourth quarter margin improvement, resolution of software issues by year end, Tariff relief from Swiss production and any use of the USD 50.0 million repurchase authorization.






Please wait processing your request...